A9606 Radium ra223 dichloride therapy
Also known as: Xofigo, Ra-223, radium therapy
Radium Ra-223 dichloride injection used therapeutically for treatment of metastatic castration-resistant prostate cancer with bone metastases.
In Plain Language
radioactive prostate cancer treatment; bone metastasis therapy
Clinical Context
Used in targeted radiotherapy for treatment of castration-resistant prostate cancer with symptomatic bone metastases.
RVU Information
CPT A9606 does not have a physician work RVU assigned by CMS. This is typical for supply, drug, and equipment codes — reimbursement is based on Average Sales Price (ASP), fee schedules, or payer contracts rather than the RVU system.
Billing & Documentation
HCPCS A-codes cover medical supplies, equipment, and transport services. Documentation must establish medical necessity and include a physician order. For durable medical equipment (DME), a Certificate of Medical Necessity (CMN) or detailed written order may be required.
Specialties
Frequently Asked Questions
What is CPT code A9606?
CPT A9606 (Radium ra223 dichloride therapy) is a A Codes code. Radium Ra-223 dichloride injection used therapeutically for treatment of metastatic castration-resistant prostate cancer with bone metastases.
Does Medicare cover A9606?
Medicare coverage for A9606 depends on medical necessity and applicable Local Coverage Determinations (LCDs). Used in targeted radiotherapy for treatment of castration-resistant prostate cancer with symptomatic bone metastases. A physician order is typically required.
When is CPT A9606 used?
Used in targeted radiotherapy for treatment of castration-resistant prostate cancer with symptomatic bone metastases.
Track This Code in RVU Edge
Log procedures, calculate wRVUs, and benchmark against national data — all in one app.
CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.